Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Gilles Frey"'
Autor:
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic activity. This open-label phase 2 study (NCT04015739) aimed to a
Externí odkaz:
https://doaj.org/article/afb66d701040478ba283ee012404613d
Autor:
Gilles Freyer, Noelia Martinez-Jañez, Bożena Kukielka-Budny, Malgorzata Ulanska, Hugues Bourgeois, Montserrat Muñoz, Serafin Morales, Juan Bayo Calero, Laura Cortesi, Tamás Pintér, Markéta Palácová, Nelli Cherciu, Edgar Petru, Johannes Ettl, Cécilia de Almeida, Gustavo Villanova, Romain Raymond, Christine Ta Thanh Minh, Ana Rodrigues, Marina E. Cazzaniga
Publikováno v:
Breast, Vol 74, Iss , Pp 103681- (2024)
Introduction: Single-agent oral vinorelbine is a standard of care for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) that has progressed on endocrine therapy. Metronomic administra
Externí odkaz:
https://doaj.org/article/0b574b9f1cb64611a2fd0d40a3bafcde
Autor:
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/c7f906a81208468d94569f0e02656fa2
Autor:
Charlotte Bellier, Laurence Gladieff, Fanny Le Du, Dominique Berton, Charlotte Bonnard, Delphine Suau, Anne-Céline Richard, Ophélie Brenner, Amir Lahouegue, Gilles Freyer, Anne Floquet, Sophie Frank, Maria Kfoury
Publikováno v:
Drugs - Real World Outcomes, Vol 10, Iss 2, Pp 207-213 (2023)
Abstract Background Olaparib, a poly(ADP-ribose) polymerase inhibitor, was approved by the European Commission in June 2019, following the results of the SOLO-1/GOG 3004 trial as maintenance monotherapy in adult patients with BRCA-mutated epithelial
Externí odkaz:
https://doaj.org/article/3c9b9e59c93c484eb7c9c1cf8bc5d447
Autor:
Olivier Colomban, Elizabeth M. Swisher, Rebecca Kristeleit, Iain McNeish, Ronnie Shapira-Frommer, Sandra Goble, Kevin K. Lin, Lara Maloney, Gilles Freyer, Benoit You
Publikováno v:
EBioMedicine, Vol 89, Iss , Pp 104477- (2023)
Summary: Background: PARP inhibitors (PARPi) have revolutionized the management of advanced ovarian carcinoma, and were investigated as forefront treatment in recurrent disease. The objective was to explore if mathematical modeling of the early longi
Externí odkaz:
https://doaj.org/article/8424b6b7464c47abaf85ca637a1499c4
Autor:
Christian Brambilla, Marie Helene Laverriere, Elisabeth Brambilla, Gilles Frey, Denis Moro, Nathalie Sturm, Sylvie Lantuejoul
Publikováno v:
Human pathology. 31(4)
Neural cell adhesion molecules (NCAM) are adhesion molecules expressed by neural and neuroendocrine tumors and a few biphasic tumors such as synovialosarcomas and breast phyllode tumors. To investigate NCAM expression in mesotheliomas, we studied 26